Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial.
[cutaneous mastocytosis]
Mastocytosis
is
frequently
associated
with
mast
cell-mediated
symptoms
which
require
relieving
medication
.
While
second
generation
antihistamines
(
sgAHs
)
are
the
first
line
therapeutic
strategy
to
treat
mast
cell
mediator-related
symptoms
,
controlled
clinical
trials
on
how
they
improve
quality
of
life
have
not
been
performed
.
This
randomized
,
double
-blind
,
placebo-controlled
,
cross-over
trial
assessed
rupatadine
20
mg
daily
in
the
treatment
of
mastocytosis
symptoms
in
30
adult
patients
.
Symptoms
were
assessed
by
a
visual
analogue
scale
(
VAS
)
and
symptom
specific
quality
of
life
questionnaire
(
ItchyQoL
)
.
The
mean
ItchyQoL
total
score
and
VAS
symptom
score
were
significantly
improved
in
the
rupatadine
treatment
phase
compared
with
placebo
.
There
were
also
significant
reductions
from
placebo
in
the
severity
of
itch
,
wheal
and
flare
,
flushing
,
tachycardia
and
headache
but
not
gastrointestinal
symptoms
.
In
this
first
comprehensive
trial
of
a
sgAH
in
mastocytosis
,
rupatadine
20
mg
daily
for
4
weeks
significantly
controlled
symptoms
and
improved
patients
'
quality
of
life
.
Diseases
Validation
Diseases presenting
"visual analogue scale"
symptom
cutaneous mastocytosis
familial mediterranean fever
pyomyositis
trochlear dysplasia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom